[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Best Sanitizers Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":70},{"warningLetters":4,"total":69},[5,31,51],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},3026,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2021-11-16T14:20:00Z\">11\u002F16\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-08T05:00:00Z\">11\u002F08\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-sanitizers-llc-614124-11082021\">Global Sanitizers LLC\u003C\u002Fa>","Division of Pharmaceutical Quality Operations IV","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Kelly Ann Lewis-Bortman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Manager\u002FCo-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Global Sanitizers LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>175 E. Warm Springs Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Las Vegas\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>89119\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:kelly@globalsanitizers.com\"> kelly@globalsanitizers.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 8, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Lewis-Bortman:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, Global Sanitizers LLC, FEI 3016413581, at 5979 S. Valley View Boulevard, Las Vegas, Nevada from February 23 to March 1, 2021.\u003C\u002Fp>\n\n\u003Cp>This inspection followed an attempt to request records and other information from your firm pursuant to section 704(a)(4) of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 374(a)(4). This request was sent to your firm on December 31, 2020. You did not respond to this request or to a second attempt to request records. Refusal to permit access to any record as required by section 704(a) is a prohibited act under section 301(e) of the FD&amp;C Act, 21 U.S.C. 331(e).\u003C\u002Fp>\n\n\u003Cp>Your firm received bulk consumer hand rub drug product (also referred to as a consumer hand sanitizer), filled this into containers, and labeled the finished drug product. During the inspection, samples of labeled and unlabeled hand sanitizer drug products manufactured and labeled at your facility and distributed in the name of your represented business entity “SBL Brands LLC”, including MEDICALLY MINDED Antimicrobial Hand Sanitizer Gel with Vitamin E &amp; Moisturizer were collected.\u003C\u002Fp>\n\n\u003Cp>The results of the FDA laboratory testing of batches of these products collected from your facility and distributed by Global Sanitizers LLC under the business name “SBL Brands LLC” demonstrate that these drug products are adulterated within the meaning of section 501(d)(2) of the FD&amp;C Act, 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003Cbr>\n\u003Cbr>\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel is an unapproved new drug in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a) and is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a).\u003C\u002Fp>\n\n\u003Cp>Furthermore, MEDICALLY MINDED Hand &amp; Surface Sanitizer Spray is misbranded under section 502(c) of the FD&amp;C Act, 21 U.S.C. 352(c), and MEDICALLY MINDED ANTIMICROBIAL Hand Sanitizer Gel and American Screening HAND SANITIZER are misbranded under section 502(i) of the FD&amp;C Act, 21 U.S.C. 352(i). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>FDA Tested Samples\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Adulteration Violations: Substitution\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Manufacturing operations at your facility included the receipt of bulk consumer hand sanitizer, which you filled into containers and labeled as the finished drug product. Based on information provided during the inspection, you received bulk hand sanitizer from several suppliers, including manufacturers located in Mexico.\u003C\u002Fp>\n\n\u003Cp>MEDICALLY MINDED Hand Sanitizer Gel Antimicrobial Formula, collected at your facility, is labeled to contain 70% volume\u002Fvolume (v\u002Fv) of the active ingredient ethyl alcohol (ethanol). However, FDA laboratory testing of a batch of this product collected during the inspection found that the drug product contained on average 0% ethanol and an average of 58% methanol v\u002Fv. Additionally, the drug product MEDICALLY MINDED Hand Sanitizer Gel Antimicrobial with Vitamin E &amp; Moisturizer, purported to be manufactured at your facility, is labeled to contain 70% v\u002Fv of the active ingredient ethyl alcohol (ethanol). However, FDA laboratory testing of this batch of this product obtained from the commercial market found that the drug product contained an average of 32% ethanol v\u002Fv and an average of 7.4% methanol v\u002Fv. Therefore, these hand sanitizer drug products are adulterated under section 501(d)(2) of the FD&amp;C Act in that the active ingredient, ethanol, was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\u003C\u002Fp>\n\n\u003Cp>Methanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidentally ingest these products, and adolescents and adults who drink these products as an alcohol (ethanol) substitute, are most at risk for methanol poisoning.\u003C\u002Fp>\n\n\u003Cp>On May 6, 2021, FDA held a teleconference with you and your legal counsel. We recommended you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market and within expiry. The FDA had previously notified the public on December 30, 2020 of the methanol contamination of your hand sanitizer drug products at the following website:\u003Cbr>\n\u003Cbr>\nhttps:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fp>\n\n\u003Cp>On May 12, 2021, you issued a voluntary nationwide recall of two MEDICALLY MINDED hand sanitizer lots due to potential presence of undeclared methanol (wood alcohol), as noted on the following FDA website:\u003C\u002Fp>\n\n\u003Cp>https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fglobal-sanitizers-issues-voluntary-nationwide-recall-medically-minded-hand-sanitizer-due-presence\u003C\u002Fp>\n\n\u003Cp>After additional communication with the FDA, on May 20, 2021, you expanded the voluntary nationwide recall of MEDICALLY MINDED hand sanitizer to include three additional lots due to potential presence of undeclared methanol (wood alcohol), as noted on the following FDA website:\u003C\u002Fp>\n\n\u003Cp>https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fmedically-minded-hand-sanitizer-nationwide-recall-expansion-due-presence-undeclared-methanol\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed investigation into how the drug products described above, and which are labeled as containing 70% ethanol, in fact was substituted in part or in whole with methanol.\u003C\u002Fli>\n\t\u003Cli>A list of all raw materials used to manufacture all of the hand sanitizer drug products you manufacture and\u002For distribute, including the suppliers’ names, addresses, and contact information.\u003C\u002Fli>\n\t\u003Cli>A list of all batches of all hand sanitizer drug products distributed in United States by your firm, and a full reconciliation of all material you distributed.\u003C\u002Fli>\n\t\u003Cli>Copies of the complete batch records for all batches distributed to the U.S.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The substitution and contamination with methanol in a drug product purported to be manufactured in your facility also demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&amp;C Act.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have not received a response from your firm for corrective actions to the observations identified during the inspection in our Form FDA 483.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Failure to Establish an Adequate Quality Unit\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm lacked written procedures describing the responsibilities of the Quality Unit (QU). Likewise, you also lacked adequate personnel responsible for Quality oversight, and review of manufacturing and testing records to approve or reject finished drug product batches. For example, testing of labeled and unlabeled hand sanitizer drug products collected from your facility as well as released product in distribution were found to be contaminated with methanol, subpotent for the labeled ethanol, and\u002For contained elevated levels of acetaldehyde\u002Facetal impurities. Failure to implement an adequate QU permitted the introduction of adulterated materials into interstate commerce.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Failure of the Quality Unit to Approve Production Procedures\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You could not provide procedures, batch records, or other records to support the manufacturing operations performed at your facility. Likewise, you had no system for assigning and tracking unique batch numbers or for the control of labels. For example, unused labels for hand sanitizer drug products were found on a labeling machine when your facility was not in a state of operation. Additionally, the marketed drug products were not labeled with batch numbers and expiry dates. The QU is responsible for approving manufacturing procedures impacting the identity, strength, quality, and purity of the drug products and for reviewing production records to assure that no errors have occurred.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Failure of the Quality Unit to Establish Adequate Controls for Released Materials\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm received bulk hand sanitizer drug products, which was filled into consumer-sized finished dosage containers and labeled for distribution to the U.S. market. You could not provide any records of the lots distributed or the number of units entered into the U.S. market.\u003C\u002Fp>\n\n\u003Cp>On a teleconference with your firm on May 6, 2021, to discuss a voluntary recall and through subsequent correspondence with the FDA, you could not immediately identify the volume of MEDICALLY MINDED hand sanitizer on the U.S. market. Ultimately, you determined that you needed to expand your original recall.\u003C\u002Fp>\n\n\u003Cp>During the inspection and in subsequent teleconferences, you stated that your firm was discontinuing operations. However, your finished drug products were still stored on site in addition to the drug products currently distributed on the market. You are still responsible for the appropriate disposition of your drug products (whether distributed or not).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Failure of the Quality Unit to Establish Adequate Control for Incoming Components\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You could not provide sufficient documentation of the quality of incoming bulk materials, including identity testing or physical inspection of your incoming component containers. In addition, you could not demonstrate that you evaluated the quality of your suppliers or the reliability of analyses received from suppliers. The QU is responsible for ensuring adequate laboratory resources for the testing and approval or rejection of components and for approving all procedures such as supplier qualification, that could impact the identity, strength, quality, and purity of the drug product.\u003C\u002Fp>\n\n\u003Cp>In summary, the CGMPs assign responsibilities to the QU which include approving or rejecting incoming materials, in-process materials, and drug products; ensuring that controls are implemented and completed satisfactorily during manufacturing operations; and reviewing production records and investigating any unexplained discrepancies. You have not demonstrated that you have a QU capable of these responsibilities.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel, MEDICALLY MINDED Hand &amp; Surface Sanitizer Spray, and MEDICALLY MINDED ANTIMICROBIAL Hand Sanitizer Gel are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as consumer topical antiseptics.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel, MEDICALLY MINDED Hand &amp; Surface Sanitizer Spray, and MEDICALLY MINDED ANTIMICROBIAL Hand Sanitizer Gel product labels that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel\u003C\u002Fstrong>\u003Cbr>\n“200 MG CANNABINOIDS 100 MG CBD + 100MG CBD . . . Drug Facts…\u003Cstrong>Use:\u003C\u002Fstrong> Hand sanitizer to help reduce bacteria on the skin. . . \u003Cstrong>Directions:\u003C\u002Fstrong> Put enough product in your palm to cover hands and rub hands together briskly until dry.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>MEDICALLY MINDED Hand &amp; Surface Sanitizer Spray\u003C\u002Fstrong>\u003Cbr>\n“Drug Facts . . . \u003Cstrong>Uses:\u003C\u002Fstrong> Hand and surface sanitizer to reduce bacteria on skin and surfaces. . . \u003Cstrong>Directions:\u003C\u002Fstrong> Wet hands thoroughly with product and allow to dry without wiping.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>MEDICALLY MINDED ANTIMICROBIAL Hand Sanitizer Gel\u003C\u002Fstrong>\u003Cbr>\n“Drug Facts . . . \u003Cstrong>Use:\u003C\u002Fstrong> Hand sanitizer to help reduce bacteria on skin . . . \u003Cstrong>Directions:\u003C\u002Fstrong> Put enough product in your palm to cover hands and rub hands together briskly until dry.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>American Screening HAND SANITIZER\u003C\u002Fstrong>\u003Cbr>\n“Drug Facts . . . \u003Cstrong>Use:\u003C\u002Fstrong> Hand sanitizer to help reduce bacteria on skin . . . \u003Cstrong>Directions:\u003C\u002Fstrong> Put enough product in your palm to cover hands and rub hands together briskly until dry.”\u003C\u002Fp>\n\n\u003Cp>MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rub proposed, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505, notably because its active ingredient CBD is not an active ingredient in any applicable final monograph or TFM described above.\u003C\u002Fp>\n\n\u003Cp>Although cannabidiol (CBD) and cannabigerol (CBG) are labeled as inactive ingredients on the label of your MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel drug product, the labeling for this product clearly represents CBD and CBG as active&nbsp; ingredients.\u003Csup>\u003Cem>\u003Cstrong>2&nbsp;&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>Specifically, your product label for MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel prominently features on the Principal Display Panel (PDP) the statement, “200 MG CANNABINOIDS 100 MG CBD + 100MG CBG.” The product label also lists, “MedicallyMindedCBD.com,” a website that markets and sells CBD products for various therapeutic benefits. As noted above, CBD and CBG are not an active ingredient in any applicable final monograph or TFM, for purposes of establishing eligibility for lawful marketing without an approved application under section 505G of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Furthermore, even if CBD or CBG could be considered an inactive ingredient in MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel, that product would still need an approved new drug application to be legally marketed because the product would not be eligible for marketing under section 505G of the FD&amp;C Act. In particular, such product would not meet the conditions under section 505G(a)(3), insofar as it would not conform with the general requirement in 21 CFR 330.1(e) that inactive ingredients must be safe and suitable.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> A suitable inactive ingredient generally provides a beneficial formulation function, such as a tablet binder or preservative, or improves product delivery (e.g., enhances absorption or controls release of the drug substance).\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> CBD or CBG has no known functional role as an inactive ingredient in a finished drug product. Additionally, an inactive ingredient should not exert pharmacological effects\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and must be safe when used at the intended dosage.\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> CBD, however, has a known pharmacological activity with demonstrated risks.\u003Csup>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> It is unknown whether the levels of CBD or CBG used in your MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel drug product has pharmacological activity or pose any concern for safety events. Accordingly, CBD or CBG cannot be considered a safe and suitable inactive ingredient as required under 21 CFR 330.1(e). Moreover, as explained above, your MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel drug product is ineligible for marketing without an approved application under section 505G of the FD&amp;C Act. Such a product does not conform with the TFM or the applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\u003Csup>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>Furthermore, MEDICALLY MINDED Hand &amp; Surface Sanitizer Spray is misbranded under section 502(c) of the FD&amp;C Act, 21 U.S.C 352(c), because the product’s Drug Facts panel contains extraneous information that goes beyond the indications described in the TFM, nor is it consistent with the indications described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency described above. Specifically, 21 CFR 201.66(d)(7) states that additional information not described in the content requirements for OTC drug products should not appear in the Drug Facts panel. However, the “Uses” section of the Drug Facts panel for MEDICALLY MINDED Hand &amp; Surface Sanitizer Spray includes extraneous information, such as under the Uses section, “. . . surface sanitizer . . . surfaces.” Conformance with general requirements for nonprescription drugs, such as 21 CFR 201.66(d)(7), is necessary in order for MEDICALLY MINDED Hand &amp; Surface Sanitizer Spray to meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505 (See section 505G(a)(3)(A)(ii)(III) (21 U.S.C. 355h(a)(3)(A)(ii)(III)).\u003C\u002Fp>\n\n\u003Cp>Additionally, MEDICALLY MINDED ANTIMICROBIAL Hand Sanitizer Gel and American Screening HAND SANITIZER are packaged in containers that resemble drinking water bottles customarily purchased by U.S. consumers.9 Section 502(i)(1) of the FD&amp;C Act, 21 U.S.C. 352(i)(1), provides that a drug is misbranded if “its container is so made, formed, or filled as to be misleading . . .” As such, your clear, colorless hand sanitizers that fill 8oz bottle containers that resemble plastic bottles ordinarily used to package drinking water are misbranded under section 502(i)(1) of the FD&amp;C Act, 21 U.S.C. 352(i)(1).\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Establishment Registration and Drug Listing Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the information obtained from the inspection, Global Sanitizers LLC (FEI 3016413581) has been identified as a repacker. Under section 510(i)(1) of the FD&amp;C Act (21 U.S.C. § 360(i)(1)), Global Sanitizers LLC is required to submit registration information annually by electronic means for each establishment you own or operate that is engaged in the manufacture, preparation, propagation, compounding, or processing of a drug that is in commercial distribution in the United States. Global Sanitizers LLC has not fulfilled the registration requirement. As a result, all drugs manufactured in this establishment are misbranded under Section 502(o) of the FD&amp;C Act [21 U.S.C. 352(o)].\u003C\u002Fp>\n\n\u003Cp>Specifically, and according to the records obtained at the time of inspection, Global Sanitizers LLC (FEI 3016413581) repackages drugs for commercial distribution in the United States which have not been properly listed with FDA as required by the law. These drugs include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>MEDICALLY MINDED Hand &amp; Surface Sanitizer Spray (2 fl oz and 4 fl oz bottles)\u003C\u002Fli>\n\t\u003Cli>MEDICALLY MINDED Hand Sanitizer Gel 2,4,8, and 16.9 fl oz bottles (containing isopropyl alcohol 70% v\u002Fv)\u003C\u002Fli>\n\t\u003Cli>MEDICALLY MINDED Hand Sanitizer Gel with Aloe Vera 8 fl oz bottles (containing ethyl alcohol 70%v\u002Fv)\u003C\u002Fli>\n\t\u003Cli>MEDICALLY MINDED Hand Sanitizer Gel 200 MG Cannabinoids\u003C\u002Fli>\n\t\u003Cli>Advanced Formula Hand Sanitizer Gel H2One Premium Hand Sanitizer 8 fl oz\u003C\u002Fli>\n\t\u003Cli>MEDICALLY MINDED Hand Sanitizer Gel ANTIMICROBIAL FORMULA 8 fl oz\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>There are no drug listing submissions under the name of or labeler code for Global Sanitizers LLC. Under section 510 of the FD&amp;C Act as amended and 21 CFR (21 U.S.C. 360(j)(1), 21 CFR 207.17 and 207.41), all drugs manufactured, prepared, propagated, compounded, or processed for U.S. commercial distribution must be listed with FDA. Failure to properly list drug products is prohibited and will render the drugs misbranded (21 U.S.C. 331(p) and 352(o)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to cease production of drugs at this facility. In response to this letter, clarify whether you intend to resume manufacturing any drugs at this facility or another in the future.\u003C\u002Fp>\n\n\u003Cp>If you plan to resume manufacturing drugs, ensure that adequate corrective actions are in place and notify this office to schedule a meeting before resuming your operations.\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, if your firm intends to resume manufacturing drugs for the U.S. market, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist in your facility. You are responsible for investigating and determining the causes of these violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct the violations cited in this letter promptly. Failure to promptly correct these violations may result in legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations in this warning letter may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>FDA may also withhold approval of requests for export certificates and approval of pending new drug applications or supplements listing your facility as a supplier or manufacturer until the above violations are corrected. We may re-inspect to verify that you have completed your corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should refer to unique identifier CMS 614124 and be sent electronically to ORAPHARM4_Responses@fda.hhs.gov or mailed to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, CA 92612\u003C\u002Fp>\n\n\u003Cp>If you have any questions regarding this letter, please contact William V. Millar, Compliance Officer, at (503) 671-9711 Ext. 30, or by email at william.millar@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nCc: SBL Brands, LLC\u003Cbr>\n175 E. Warm Springs Road\u003Cbr>\nLas Vegas, NV 89119\u003C\u002Fp>\n\n\u003Cp>______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1 \u003C\u002Fstrong>\u003C\u002Fem>Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) \u003C\u002Fem>on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the contamination of hand sanitizer products manufactured and\u002For distributed at your facility, a review of the purported formulations on the drug products’ labeling further indicates that such products are not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, these products do not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under 21 CFR 201.66(b), an active ingredient is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> 21 CFR 330.1(e) requires that \"the product contains only suitable inactive ingredients which are safe in the amounts administered and do not interfere with the effectiveness of the preparation or with suitable tests or assays to determine if the product meets its professed standards of identity, strength, quality, and purity.\"\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See e.g., \"\u003Cem>Using the Inactive Ingredient Database\u003C\u002Fem>\" Guidance for Industry (July 2019), p. 1 at&nbsp;https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F128687\u002Fdownload, and \"\u003Cem>Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients\u003C\u002Fem>\" Guidance for Industry (May 2005), pp. 1-2 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F72260\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5 \u003C\u002Fstrong>\u003C\u002Fem>See e.g., 21 CFR 314.3(b) and 21 CFR 210.3(b)(7), which define an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man.” All other components of a finished drug product are considered inactive ingredients (see CFR 314.3(b), 21 CFR 210.3(b)(8)).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 330.1(e).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> For example, the labeling for Epidiolex (cannabidiol) prescription oral solution includes risks for the drug such as liver injury, interactions with other drugs or supplements, potential for male reproductive toxicity, somnolence, insomnia, diarrhea, decreased appetite, abdominal pain, upset stomach, changes in mood, irritability, and agitation. See&nbsp;https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2020\u002F210365s005s006s007lbl.pdf.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel is not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>9\u003C\u002Fstrong>\u003C\u002Fem> FDA is concerned that OTC hand sanitizer drug products packaged in containers that resemble drink containers commonly used by adults and children may confuse or mislead consumers and, thereby, increase the risk of accidental ingestion. Please refer to the August 27, 2020 news release titled, “COVID-19 Update: FDA Warns Consumers About Hand Sanitizer Packaged in Food and Drink Containers,” see https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpress-announcements\u002Fcovid-19-update-fda-warns-consumers-about-handsanitizer-packaged-food-and-drink-containers, that warns consumers about alcohol-based hand sanitizers packaged in containers that resemble food or drink containers customarily purchased by U.S. consumers may put consumers at risk of serious injury or death if ingested.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Kelly Ann Lewis-Bortman\n\nRecipient Title\n\nManager\u002FCo-Owner\n\nGlobal Sanitizers LLC\n\n175 E. Warm Springs Road\n\nLas Vegas, NV 89119\n\nUnited States\n\nkelly@globalsanitizers.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nNovember 8, 2021\n\nDear Ms. Lewis-Bortman:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, Global Sanitizers LLC, FEI 3016413581, at 5979 S. Valley View Boulevard, Las Vegas, Nevada from February 23 to March 1, 2021.\n\nThis inspection followed an attempt to request records and other information from your firm pursuant to section 704(a)(4) of the Federal Food, Drug and Cosmetic Act (FD&C Act), 21 U.S.C. 374(a)(4). This request was sent to your firm on December 31, 2020. You did not respond to this request or to a second attempt to request records. Refusal to permit access to any record as required by section 704(a) is a prohibited act under section 301(e) of the FD&C Act, 21 U.S.C. 331(e).\n\nYour firm received bulk consumer hand rub drug product (also referred to as a consumer hand sanitizer), filled this into containers, and labeled the finished drug product. During the inspection, samples of labeled and unlabeled hand sanitizer drug products manufactured and labeled at your facility and distributed in the name of your represented business entity “SBL Brands LLC”, including MEDICALLY MINDED Antimicrobial Hand Sanitizer Gel with Vitamin E & Moisturizer were collected.\n\nThe results of the FDA laboratory testing of batches of these products collected from your facility and distributed by Global Sanitizers LLC under the business name “SBL Brands LLC” demonstrate that these drug products are adulterated within the meaning of section 501(d)(2) of the FD&C Act, 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor.\n\nThis warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nIn addition, MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel is an unapproved new drug in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a) and is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a).\n\nFurthermore, MEDICALLY MINDED Hand & Surface Sanitizer Spray is misbranded under section 502(c) of the FD&C Act, 21 U.S.C. 352(c), and MEDICALLY MINDED ANTIMICROBIAL Hand Sanitizer Gel and American Screening HAND SANITIZER are misbranded under section 502(i) of the FD&C Act, 21 U.S.C. 352(i). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\n\nFDA Tested Samples\n\nAdulteration Violations: Substitution\n\nManufacturing operations at your facility included the receipt of bulk consumer hand sanitizer, which you filled into containers and labeled as the finished drug product. Based on information provided during the inspection, you received bulk hand sanitizer from several suppliers, including manufacturers located in Mexico.\n\nMEDICALLY MINDED Hand Sanitizer Gel Antimicrobial Formula, collected at your facility, is labeled to contain 70% volume\u002Fvolume (v\u002Fv) of the active ingredient ethyl alcohol (ethanol). However, FDA laboratory testing of a batch of this product collected during the inspection found that the drug product contained on average 0% ethanol and an average of 58% methanol v\u002Fv. Additionally, the drug product MEDICALLY MINDED Hand Sanitizer Gel Antimicrobial with Vitamin E & Moisturizer, purported to be manufactured at your facility, is labeled to contain 70% v\u002Fv of the active ingredient ethyl alcohol (ethanol). However, FDA laboratory testing of this batch of this product obtained from the commercial market found that the drug product contained an average of 32% ethanol v\u002Fv and an average of 7.4% methanol v\u002Fv. Therefore, these hand sanitizer drug products are adulterated under section 501(d)(2) of the FD&C Act in that the active ingredient, ethanol, was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\n\nMethanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidentally ingest these products, and adolescents and adults who drink these products as an alcohol (ethanol) substitute, are most at risk for methanol poisoning.\n\nOn May 6, 2021, FDA held a teleconference with you and your legal counsel. We recommended you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market and within expiry. The FDA had previously notified the public on December 30, 2020 of the methanol contamination of your hand sanitizer drug products at the following website:\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\n\nOn May 12, 2021, you issued a voluntary nationwide recall of two MEDICALLY MINDED hand sanitizer lots due to potential presence of undeclared methanol (wood alcohol), as noted on the following FDA website:\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fglobal-sanitizers-issues-voluntary-nationwide-recall-medically-minded-hand-sanitizer-due-presence\n\nAfter additional communication with the FDA, on May 20, 2021, you expanded the voluntary nationwide recall of MEDICALLY MINDED hand sanitizer to include three additional lots due to potential presence of undeclared methanol (wood alcohol), as noted on the following FDA website:\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fmedically-minded-hand-sanitizer-nationwide-recall-expansion-due-presence-undeclared-methanol\n\nIn response to this letter, provide the following:\n\nA detailed investigation into how the drug products described above, and which are labeled as containing 70% ethanol, in fact was substituted in part or in whole with methanol.\n\nA list of all raw materials used to manufacture all of the hand sanitizer drug products you manufacture and\u002For distribute, including the suppliers’ names, addresses, and contact information.\n\nA list of all batches of all hand sanitizer drug products distributed in United States by your firm, and a full reconciliation of all material you distributed.\n\nCopies of the complete batch records for all batches distributed to the U.S.\n\nThe substitution and contamination with methanol in a drug product purported to be manufactured in your facility also demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&C Act.1\n\nCGMP Violations\n\nWe have not received a response from your firm for corrective actions to the observations identified during the inspection in our Form FDA 483.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nFailure to Establish an Adequate Quality Unit\n\nYour firm lacked written procedures describing the responsibilities of the Quality Unit (QU). Likewise, you also lacked adequate personnel responsible for Quality oversight, and review of manufacturing and testing records to approve or reject finished drug product batches. For example, testing of labeled and unlabeled hand sanitizer drug products collected from your facility as well as released product in distribution were found to be contaminated with methanol, subpotent for the labeled ethanol, and\u002For contained elevated levels of acetaldehyde\u002Facetal impurities. Failure to implement an adequate QU permitted the introduction of adulterated materials into interstate commerce.\n\nFailure of the Quality Unit to Approve Production Procedures\n\nYou could not provide procedures, batch records, or other records to support the manufacturing operations performed at your facility. Likewise, you had no system for assigning and tracking unique batch numbers or for the control of labels. For example, unused labels for hand sanitizer drug products were found on a labeling machine when your facility was not in a state of operation. Additionally, the marketed drug products were not labeled with batch numbers and expiry dates. The QU is responsible for approving manufacturing procedures impacting the identity, strength, quality, and purity of the drug products and for reviewing production records to assure that no errors have occurred.\n\nFailure of the Quality Unit to Establish Adequate Controls for Released Materials\n\nYour firm received bulk hand sanitizer drug products, which was filled into consumer-sized finished dosage containers and labeled for distribution to the U.S. market. You could not provide any records of the lots distributed or the number of units entered into the U.S. market.\n\nOn a teleconference with your firm on May 6, 2021, to discuss a voluntary recall and through subsequent correspondence with the FDA, you could not immediately identify the volume of MEDICALLY MINDED hand sanitizer on the U.S. market. Ultimately, you determined that you needed to expand your original recall.\n\nDuring the inspection and in subsequent teleconferences, you stated that your firm was discontinuing operations. However, your finished drug products were still stored on site in addition to the drug products currently distributed on the market. You are still responsible for the appropriate disposition of your drug products (whether distributed or not).\n\nFailure of the Quality Unit to Establish Adequate Control for Incoming Components\n\nYou could not provide sufficient documentation of the quality of incoming bulk materials, including identity testing or physical inspection of your incoming component containers. In addition, you could not demonstrate that you evaluated the quality of your suppliers or the reliability of analyses received from suppliers. The QU is responsible for ensuring adequate laboratory resources for the testing and approval or rejection of components and for approving all procedures such as supplier qualification, that could impact the identity, strength, quality, and purity of the drug product.\n\nIn summary, the CGMPs assign responsibilities to the QU which include approving or rejecting incoming materials, in-process materials, and drug products; ensuring that controls are implemented and completed satisfactorily during manufacturing operations; and reviewing production records and investigating any unexplained discrepancies. You have not demonstrated that you have a QU capable of these responsibilities.\n\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide the following:\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\nUnapproved New Drug and Misbranding Violations\n\nMEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel, MEDICALLY MINDED Hand & Surface Sanitizer Spray, and MEDICALLY MINDED ANTIMICROBIAL Hand Sanitizer Gel are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as consumer topical antiseptics.\n\nExamples of claims observed on MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel, MEDICALLY MINDED Hand & Surface Sanitizer Spray, and MEDICALLY MINDED ANTIMICROBIAL Hand Sanitizer Gel product labels that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\n\nMEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel\n\n“200 MG CANNABINOIDS 100 MG CBD + 100MG CBD . . . Drug Facts…Use: Hand sanitizer to help reduce bacteria on the skin. . . Directions: Put enough product in your palm to cover hands and rub hands together briskly until dry.”\n\nMEDICALLY MINDED Hand & Surface Sanitizer Spray\n\n“Drug Facts . . . Uses: Hand and surface sanitizer to reduce bacteria on skin and surfaces. . . Directions: Wet hands thoroughly with product and allow to dry without wiping.”\n\nMEDICALLY MINDED ANTIMICROBIAL Hand Sanitizer Gel\n\n“Drug Facts . . . Use: Hand sanitizer to help reduce bacteria on skin . . . Directions: Put enough product in your palm to cover hands and rub hands together briskly until dry.”\n\nAmerican Screening HAND SANITIZER\n\n“Drug Facts . . . Use: Hand sanitizer to help reduce bacteria on skin . . . Directions: Put enough product in your palm to cover hands and rub hands together briskly until dry.”\n\nMEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rub proposed, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505, notably because its active ingredient CBD is not an active ingredient in any applicable final monograph or TFM described above.\n\nAlthough cannabidiol (CBD) and cannabigerol (CBG) are labeled as inactive ingredients on the label of your MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel drug product, the labeling for this product clearly represents CBD and CBG as active ingredients.2 Specifically, your product label for MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel prominently features on the Principal Display Panel (PDP) the statement, “200 MG CANNABINOIDS 100 MG CBD + 100MG CBG.” The product label also lists, “MedicallyMindedCBD.com,” a website that markets and sells CBD products for various therapeutic benefits. As noted above, CBD and CBG are not an active ingredient in any applicable final monograph or TFM, for purposes of establishing eligibility for lawful marketing without an approved application under section 505G of the FD&C Act.\n\nFurthermore, even if CBD or CBG could be considered an inactive ingredient in MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel, that product would still need an approved new drug application to be legally marketed because the product would not be eligible for marketing under section 505G of the FD&C Act. In particular, such product would not meet the conditions under section 505G(a)(3), insofar as it would not conform with the general requirement in 21 CFR 330.1(e) that inactive ingredients must be safe and suitable.3 A suitable inactive ingredient generally provides a beneficial formulation function, such as a tablet binder or preservative, or improves product delivery (e.g., enhances absorption or controls release of the drug substance).4 CBD or CBG has no known functional role as an inactive ingredient in a finished drug product. Additionally, an inactive ingredient should not exert pharmacological effects5 and must be safe when used at the intended dosage.6 CBD, however, has a known pharmacological activity with demonstrated risks.7 It is unknown whether the levels of CBD or CBG used in your MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel drug product has pharmacological activity or pose any concern for safety events. Accordingly, CBD or CBG cannot be considered a safe and suitable inactive ingredient as required under 21 CFR 330.1(e). Moreover, as explained above, your MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel drug product is ineligible for marketing without an approved application under section 505G of the FD&C Act. Such a product does not conform with the TFM or the applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.8\n\nMEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nFurthermore, MEDICALLY MINDED Hand & Surface Sanitizer Spray is misbranded under section 502(c) of the FD&C Act, 21 U.S.C 352(c), because the product’s Drug Facts panel contains extraneous information that goes beyond the indications described in the TFM, nor is it consistent with the indications described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency described above. Specifically, 21 CFR 201.66(d)(7) states that additional information not described in the content requirements for OTC drug products should not appear in the Drug Facts panel. However, the “Uses” section of the Drug Facts panel for MEDICALLY MINDED Hand & Surface Sanitizer Spray includes extraneous information, such as under the Uses section, “. . . surface sanitizer . . . surfaces.” Conformance with general requirements for nonprescription drugs, such as 21 CFR 201.66(d)(7), is necessary in order for MEDICALLY MINDED Hand & Surface Sanitizer Spray to meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505 (See section 505G(a)(3)(A)(ii)(III) (21 U.S.C. 355h(a)(3)(A)(ii)(III)).\n\nAdditionally, MEDICALLY MINDED ANTIMICROBIAL Hand Sanitizer Gel and American Screening HAND SANITIZER are packaged in containers that resemble drinking water bottles customarily purchased by U.S. consumers.9 Section 502(i)(1) of the FD&C Act, 21 U.S.C. 352(i)(1), provides that a drug is misbranded if “its container is so made, formed, or filled as to be misleading . . .” As such, your clear, colorless hand sanitizers that fill 8oz bottle containers that resemble plastic bottles ordinarily used to package drinking water are misbranded under section 502(i)(1) of the FD&C Act, 21 U.S.C. 352(i)(1).\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nEstablishment Registration and Drug Listing Violations\n\nBased upon the information obtained from the inspection, Global Sanitizers LLC (FEI 3016413581) has been identified as a repacker. Under section 510(i)(1) of the FD&C Act (21 U.S.C. § 360(i)(1)), Global Sanitizers LLC is required to submit registration information annually by electronic means for each establishment you own or operate that is engaged in the manufacture, preparation, propagation, compounding, or processing of a drug that is in commercial distribution in the United States. Global Sanitizers LLC has not fulfilled the registration requirement. As a result, all drugs manufactured in this establishment are misbranded under Section 502(o) of the FD&C Act [21 U.S.C. 352(o)].\n\nSpecifically, and according to the records obtained at the time of inspection, Global Sanitizers LLC (FEI 3016413581) repackages drugs for commercial distribution in the United States which have not been properly listed with FDA as required by the law. These drugs include:\n\nMEDICALLY MINDED Hand & Surface Sanitizer Spray (2 fl oz and 4 fl oz bottles)\n\nMEDICALLY MINDED Hand Sanitizer Gel 2,4,8, and 16.9 fl oz bottles (containing isopropyl alcohol 70% v\u002Fv)\n\nMEDICALLY MINDED Hand Sanitizer Gel with Aloe Vera 8 fl oz bottles (containing ethyl alcohol 70%v\u002Fv)\n\nMEDICALLY MINDED Hand Sanitizer Gel 200 MG Cannabinoids\n\nAdvanced Formula Hand Sanitizer Gel H2One Premium Hand Sanitizer 8 fl oz\n\nMEDICALLY MINDED Hand Sanitizer Gel ANTIMICROBIAL FORMULA 8 fl oz\n\nThere are no drug listing submissions under the name of or labeler code for Global Sanitizers LLC. Under section 510 of the FD&C Act as amended and 21 CFR (21 U.S.C. 360(j)(1), 21 CFR 207.17 and 207.41), all drugs manufactured, prepared, propagated, compounded, or processed for U.S. commercial distribution must be listed with FDA. Failure to properly list drug products is prohibited and will render the drugs misbranded (21 U.S.C. 331(p) and 352(o)).\n\nDrug Production Ceased\n\nWe acknowledge your commitment to cease production of drugs at this facility. In response to this letter, clarify whether you intend to resume manufacturing any drugs at this facility or another in the future.\n\nIf you plan to resume manufacturing drugs, ensure that adequate corrective actions are in place and notify this office to schedule a meeting before resuming your operations.\n\nBased upon the nature of the violations we identified at your firm, if your firm intends to resume manufacturing drugs for the U.S. market, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist in your facility. You are responsible for investigating and determining the causes of these violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect the violations cited in this letter promptly. Failure to promptly correct these violations may result in legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations in this warning letter may also prevent other Federal agencies from awarding contracts.\n\nFDA may also withhold approval of requests for export certificates and approval of pending new drug applications or supplements listing your facility as a supplier or manufacturer until the above violations are corrected. We may re-inspect to verify that you have completed your corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour response should refer to unique identifier CMS 614124 and be sent electronically to ORAPHARM4_Responses@fda.hhs.gov or mailed to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food and Drug Administration\n\n19701 Fairchild Road\n\nIrvine, CA 92612\n\nIf you have any questions regarding this letter, please contact William V. Millar, Compliance Officer, at (503) 671-9711 Ext. 30, or by email at william.millar@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Steven E. Porter, Jr\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nCc: SBL Brands, LLC\n\n175 E. Warm Springs Road\n\nLas Vegas, NV 89119\n\n______________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the contamination of hand sanitizer products manufactured and\u002For distributed at your facility, a review of the purported formulations on the drug products’ labeling further indicates that such products are not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, these products do not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n2 Under 21 CFR 201.66(b), an active ingredient is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\n3 21 CFR 330.1(e) requires that \"the product contains only suitable inactive ingredients which are safe in the amounts administered and do not interfere with the effectiveness of the preparation or with suitable tests or assays to determine if the product meets its professed standards of identity, strength, quality, and purity.\"\n\n4 See e.g., \"Using the Inactive Ingredient Database\" Guidance for Industry (July 2019), p. 1 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F128687\u002Fdownload, and \"Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients\" Guidance for Industry (May 2005), pp. 1-2 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F72260\u002Fdownload.\n\n5 See e.g., 21 CFR 314.3(b) and 21 CFR 210.3(b)(7), which define an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man.” All other components of a finished drug product are considered inactive ingredients (see CFR 314.3(b), 21 CFR 210.3(b)(8)).\n\n6 See 21 CFR 330.1(e).\n\n7 For example, the labeling for Epidiolex (cannabidiol) prescription oral solution includes risks for the drug such as liver injury, interactions with other drugs or supplements, potential for male reproductive toxicity, somnolence, insomnia, diarrhea, decreased appetite, abdominal pain, upset stomach, changes in mood, irritability, and agitation. See https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2020\u002F210365s005s006s007lbl.pdf.\n\n8 See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel is not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.\n\n9 FDA is concerned that OTC hand sanitizer drug products packaged in containers that resemble drink containers commonly used by adults and children may confuse or mislead consumers and, thereby, increase the risk of accidental ingestion. Please refer to the August 27, 2020 news release titled, “COVID-19 Update: FDA Warns Consumers About Hand Sanitizer Packaged in Food and Drink Containers,” see https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpress-announcements\u002Fcovid-19-update-fda-warns-consumers-about-handsanitizer-packaged-food-and-drink-containers, that warns consumers about alcohol-based hand sanitizers packaged in containers that resemble food or drink containers customarily purchased by U.S. consumers may put consumers at risk of serious injury or death if ingested.","Global Sanitizers LLC","global-sanitizers-llc-614124-11082021","2026-08-18T06:42:29.386127+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-sanitizers-llc-614124-11082021","2026-10-26T08:08:46.779727+00:00","Warning Letter","Issued","2021-11-16","614124","Drugs","Ms. Kelly Ann Lewis-Bortman","2026-08-20T02:26:23.323+00:00","Via Email","2021-11-08",{"id":32,"raw":33,"subject":12,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":47,"body_fetched_at":48,"delivery_method":49,"recipient_title":19,"reference_number":19,"action_taken_date":50,"medical_device_id":19,"response_letter_date":19},2455,[34,35,36,37,12,13,13,13],"\u003Ctime datetime=\"2022-09-13T13:20:00Z\">09\u002F13\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-09-02T04:00:00Z\">09\u002F02\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsanitizer-supply-llc-633583-09022022\">Sanitizer Supply LLC\u003C\u002Fa>","Office of Pharmaceutical Quality Operations, Division II","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ian Malpass\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sanitizer Supply LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2780 Horizon Ridge Court\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Suwanee\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30024-3569\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Pharmaceutical Quality Operations, Division II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>DATE: September 2, 2022\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Case #: 633583\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Malpass:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, Sanitizer Supply LLC, FEI 3017183921, at 2780 Horizon Ridge Court, Suwanee, from March 24 to March 31, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your April 28, 2022, response to our Form FDA 483. Although you mentioned that you have engaged the services of a consultant and you will cease manufacturing operations, you have not provided specific information or evidence of corrective actions to the observations identified during the inspection on our Form FDA 483.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug\u003C\u002Fstrong>&nbsp;\u003Cstrong>product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufacture over-the-counter (OTC) drug products including benzalkonium chloride-based (BZK) hand sanitizing wipes and alcohol-based hand sanitizers and repackage hand sanitizer drug products under contract.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> You failed to perform potency and microbial testing for your BZK hand sanitizing wipes prior to release for distribution. You released your BZK hand sanitizing wipes based on a \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, in your signed affidavit, you stated that you did not have final product testing results for BZK hand sanitizing wipes.\u003C\u002Fp>\n\n\u003Cp>Testing is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes that are appropriate for their intended use, including microbiological specifications.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and (2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to test incoming components and active ingredients (e.g., BZK) for identity. This was confirmed in your signed affidavit provided to our investigator. Your firm relied on the certificates of analysis (COA) from unqualified suppliers without establishing the reliability of each of your suppliers’ COA for the component specifications and characteristics.\u003C\u002Fp>\n\n\u003Cp>Identity testing is required for each component lot prior to use in drug product manufacturing, and you can only rely on a COA for other component attributes through validation of supplier’s test results at appropriate intervals.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. Your firm failed to establish an adequate quality unit (QU) with responsibilities to ensure adequate oversight for the manufacture of your drug products. For example, your QU failed to train and ensure that your Customer Service personnel responsible for complaint handling follow your customer complaint procedure. The procedure states that \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, during the inspection, your Customer Service personnel told our investigator that they have not received formal training on the procedure, and that they confer with the QU on how to handle complaints. Additionally, your complaint procedure lacked requirements to indicate how the review should be conducted as well as how to classify the severity of complaints.\u003C\u002Fp>\n\n\u003Cp>In addition, in a signed affidavit, you stated that your firm lacks numerous documents applicable to the QU including, but not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Annual Product Reviews\u003C\u002Fli>\n\t\u003Cli>CGMP records including training records\u003C\u002Fli>\n\t\u003Cli>Stability studies establishing expiration date for BZK hand sanitizing wipes and other drug products, and\u003C\u002Fli>\n\t\u003Cli>Master batch records\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to cease production of drugs at this facility. However, your firm continues to be registered as a manufacturer. In response to this letter, clarify whether you intend to resume manufacturing any drugs at this facility or another in the future.\u003C\u002Fp>\n\n\u003Cp>If you plan to resume manufacturing drugs, ensure that adequate corrective actions are in place and notify this office to schedule a meeting before resuming your operations.\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, if your firm intends to resume manufacturing drugs for the U.S. market, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance, and that the consultant evaluates the completion and efficacy of any identified corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Contract Manufacturers\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. The FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. The FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to address this matter promptly and adequately may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to case # \u003Cstrong>633583\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Please electronically submit your reply, on company letterhead, to Rebecca Asente, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov. In addition, please submit a signed copy of your response to Rebecca.asente@fda.hhs.gov and ORApharm2actingdcb@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Rebecca Asente via (504) 846-8104 or Rebecca.asente@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Monica R. Maxwell\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations, Division II\u003C\u002Fp>\n\n\u003Cp>CC:\u003C\u002Fp>\n\n\u003Cp>Nicolas M. Nunez\u003Cbr>\nExecutive Vice President\u003Cbr>\nSanitizer Supply LLC\u003Cbr>\n2780 Horizon Ridge Court\u003Cbr>\nSuwanee, Georgia 30024-3569\u003C\u002Fp>\n\n\u003Cp>James C. Fraser, Regulatory Counsel\u003Cbr>\nGreenberg Traurig LLP\u003Cbr>\n2101 L Street N.W.\u003Cbr>\nWashington D.C. 20037\u003C\u002Fp>\n\n\u003Cp>________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cstrong>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fstrong> on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (\u003Cstrong>86 Fed Reg at 56960\u003C\u002Fstrong>). This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. A review of the formulations of the drug products indicates that such products are not prepared consistent with FDA’s temporary policy set forth in the guidance.&nbsp;Because Sanitizer Supply LLC’s hand sanitizer products are not consistent with the formulations described in these guidances, they do not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nIan Malpass\n\nRecipient Title\n\nPresident\n\nSanitizer Supply LLC\n\n2780 Horizon Ridge Court\n\nSuwanee, GA 30024-3569\n\nUnited States\n\nIssuing Office:\n\nOffice of Pharmaceutical Quality Operations, Division II\n\nUnited States\n\nDATE: September 2, 2022\n\nCase #: 633583\n\nWARNING LETTER\n\nDear Mr. Malpass:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, Sanitizer Supply LLC, FEI 3017183921, at 2780 Horizon Ridge Court, Suwanee, from March 24 to March 31, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe acknowledge receipt of your April 28, 2022, response to our Form FDA 483. Although you mentioned that you have engaged the services of a consultant and you will cease manufacturing operations, you have not provided specific information or evidence of corrective actions to the observations identified during the inspection on our Form FDA 483.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\n\nYou manufacture over-the-counter (OTC) drug products including benzalkonium chloride-based (BZK) hand sanitizing wipes and alcohol-based hand sanitizers and repackage hand sanitizer drug products under contract.1 You failed to perform potency and microbial testing for your BZK hand sanitizing wipes prior to release for distribution. You released your BZK hand sanitizing wipes based on a (b)(4). Additionally, in your signed affidavit, you stated that you did not have final product testing results for BZK hand sanitizing wipes.\n\nTesting is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes that are appropriate for their intended use, including microbiological specifications.\n\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and (2)).\n\nYou failed to test incoming components and active ingredients (e.g., BZK) for identity. This was confirmed in your signed affidavit provided to our investigator. Your firm relied on the certificates of analysis (COA) from unqualified suppliers without establishing the reliability of each of your suppliers’ COA for the component specifications and characteristics.\n\nIdentity testing is required for each component lot prior to use in drug product manufacturing, and you can only rely on a COA for other component attributes through validation of supplier’s test results at appropriate intervals.\n\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour firm’s quality systems are inadequate. Your firm failed to establish an adequate quality unit (QU) with responsibilities to ensure adequate oversight for the manufacture of your drug products. For example, your QU failed to train and ensure that your Customer Service personnel responsible for complaint handling follow your customer complaint procedure. The procedure states that (b)(4). However, during the inspection, your Customer Service personnel told our investigator that they have not received formal training on the procedure, and that they confer with the QU on how to handle complaints. Additionally, your complaint procedure lacked requirements to indicate how the review should be conducted as well as how to classify the severity of complaints.\n\nIn addition, in a signed affidavit, you stated that your firm lacks numerous documents applicable to the QU including, but not limited to:\n\nAnnual Product Reviews\n\nCGMP records including training records\n\nStability studies establishing expiration date for BZK hand sanitizing wipes and other drug products, and\n\nMaster batch records\n\nAn adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nDrug Production Ceased\n\nWe acknowledge your commitment to cease production of drugs at this facility. However, your firm continues to be registered as a manufacturer. In response to this letter, clarify whether you intend to resume manufacturing any drugs at this facility or another in the future.\n\nIf you plan to resume manufacturing drugs, ensure that adequate corrective actions are in place and notify this office to schedule a meeting before resuming your operations.\n\nBased upon the nature of the violations we identified at your firm, if your firm intends to resume manufacturing drugs for the U.S. market, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance, and that the consultant evaluates the completion and efficacy of any identified corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nContract Manufacturers\n\nDrugs must be manufactured in conformance with CGMP. The FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. The FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to address this matter promptly and adequately may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour written notification should refer to case # 633583.\n\nPlease electronically submit your reply, on company letterhead, to Rebecca Asente, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov. In addition, please submit a signed copy of your response to Rebecca.asente@fda.hhs.gov and ORApharm2actingdcb@fda.hhs.gov.\n\nIf you have questions regarding the contents of this letter, you may contact Rebecca Asente via (504) 846-8104 or Rebecca.asente@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMonica R. Maxwell\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations, Division II\n\nCC:\n\nNicolas M. Nunez\n\nExecutive Vice President\n\nSanitizer Supply LLC\n\n2780 Horizon Ridge Court\n\nSuwanee, Georgia 30024-3569\n\nJames C. Fraser, Regulatory Counsel\n\nGreenberg Traurig LLP\n\n2101 L Street N.W.\n\nWashington D.C. 20037\n\n________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. A review of the formulations of the drug products indicates that such products are not prepared consistent with FDA’s temporary policy set forth in the guidance. Because Sanitizer Supply LLC’s hand sanitizer products are not consistent with the formulations described in these guidances, they do not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.","Sanitizer Supply LLC","sanitizer-supply-llc-633583-09022022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsanitizer-supply-llc-633583-09022022","2026-10-26T08:09:53.678854+00:00","2022-09-13","633583","Ian Malpass","2026-08-20T01:34:57.671+00:00","VIA Electronic Mail","2022-09-02",{"id":52,"raw":53,"subject":12,"body_html":57,"body_text":58,"firm_name":59,"letter_id":60,"created_at":18,"fei_number":19,"letter_url":61,"updated_at":62,"action_type":22,"case_status":23,"posted_date":63,"marcs_cms_no":64,"product_type":65,"closeout_date":19,"issuing_office":11,"recipient_name":66,"body_fetched_at":67,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":68,"medical_device_id":19,"response_letter_date":19},3015,[54,55,56,11,12,13,13,13],"\u003Ctime datetime=\"2021-11-23T14:20:00Z\">11\u002F23\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-09-24T04:00:00Z\">09\u002F24\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchameleon-beverage-co-inc-dba-chameleon-sanitizer-corporation-615066-09242021\">Chameleon Beverage Co. Inc. dba Chameleon Sanitizer Corporation\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Derek W. Reineman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Chameleon Beverage Co. Inc. dba Chameleon Sanitizer Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6444 E. 26th St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Commerce\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90040\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:derekreineman@chameleonbeverage.com\"> derekreineman@chameleonbeverage.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 24, 2021\u003Cbr>\n\u003Cbr>\nDear Mr. Reineman:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, Chameleon Beverage Co. Inc. dba Chameleon Sanitizer Corporation, FEI: 3004378632, at 6444 E. 26th St, Commerce, California, from March 29 to April 2, 2021.\u003C\u002Fp>\n\n\u003Cp>FDA determined that hand sanitizer drug products\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> manufactured at your facility were adulterated within the meaning of section 501(a)(2)(A) of the Federal Food, Drug, and Cosmetic (FD&amp;C) Act, 21 U.S.C. 351(a)(2)(A), in that a substance was prepared, packed, or held under insanitary conditions.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, ALKEMI HAND SANITIZER GEL packaged in 33.8oz containers is misbranded under section 502(i) of the FD&amp;C Act, 21 U.S.C. 352(i). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). This violation is described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Insanitary Conditions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your hand sanitizer drug products were adulterated under section 501(a)(2)(A) of the FD&amp;C Act because they were prepared, packed, or held under insanitary conditions. You manufactured batches of hand sanitizer in an unlit \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> was not \u003Cstrong>(b)(4)\u003C\u002Fstrong> and was therefore exposed to the outside environment. Filling was performed by inserting a manual pump into a tote of bulk drug product which was left open to the environment during set-up. You did not have any controls in place to prevent contamination of the production environment and the drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We reviewed your April 23, 2021, response to our Form FDA 483 in detail.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our investigators observed that your quality unit (QU) did not provide adequate oversight for the manufacture of your over-the-counter (OTC) drug products. Your firm manufactured hand sanitizer drug products without performing identification testing of the incoming component and without verification of your supplier’s certificates of analysis (COA). Further, you did not establish specifications for the drug product and distributed finished hand sanitizer drug products without performing release testing.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that, your agreement with your customer provides that responsibility for hand sanitizer compliance and efficacy rests with your customer. Specifically, both ensuring the quality of incoming components and establishing finished product specifications are the responsibility of your customer. Likewise, you stated that because your customer did not finalize its hand sanitizer formulation and provide finished product specifications, your final product specifications had not been established. As a contract manufacturer, under CGMP, you should not have commenced manufacturing until key quality requirements such as operations and specifications were in place.\u003C\u002Fp>\n\n\u003Cp>Your QU has the responsibility to ensure the quality of components used by your facility and evaluate the quality of finished products to make approval or rejection decisions about each batch. You have quality agreements with several customers regarding the manufacture of hand sanitizer drug products. As a contract manufacturer, quality agreements cannot be used to delegate statutory or regulatory responsibilities to comply with CGMP. You are responsible for the quality of drugs you produce as a contract facility, regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n&nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>• A list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before making a lot disposition decision, and the associated written procedures.\u003C\u002Fp>\n\n\u003Cp>• The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fp>\n\n\u003Cp>• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fp>\n\n\u003Cp>• A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\u003C\u002Fp>\n\n\u003Cp>• A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactured batches of hand sanitizer by attaching a manual pump to a tote of bulk hand sanitizer for bottle filling. During the inspection, you could not provide cleaning records for the manual pump. Additionally, you could not provide procedures for cleaning and cleaning validation studies for this equipment. The manual pump was observed to be wrapped in plastic tape and rubber gloves and was located in an unlit \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Bulk hand sanitizer received from several suppliers were filled using this equipment.\u003C\u002Fp>\n\n\u003Cp>Further, your firm manufactured hand sanitizer drug products on filling line \u003Cstrong>(b)(4)\u003C\u002Fstrong> which is also used to manufacture non-pharmaceutical products (i.e., bottled drinking water). During the inspection, you provided an interim cleaning procedure which lacked sufficient detail to ensure adequate cleaning. You also failed to provide validation studies for this cleaning procedure to ensure that cross-contamination does not occur between hand sanitizer drug products and bottled drinking water.\u003C\u002Fp>\n\n\u003Cp>In your response, you provided a manual pump cleaning procedure that described rinsing the pump with \u003Cstrong>(b)(4)\u003C\u002Fstrong> water until the rinse water meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> and passes microbial testing. You did not provide validation studies for this method and did not address the adequacy of this method for preventing chemical carry over. Your response did not include a retrospective analysis of the cross-contamination risk between your various drug products and non-drug products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product, including both non-drug products and finished drug products.\u003C\u002Fp>\n\n\u003Cp>• A corrective action preventive action (CAPA) plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>ALKEMI HAND SANITIZER GEL is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a consumer topical antiseptic.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the ALKEMI HAND SANITIZER GEL product label that provides evidence of the intended uses (as defined in 21 CFR 201.128) of the product includes, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“Drug Facts . . . \u003Cstrong>Uses\u003C\u002Fstrong>: • hand sanitizer to reduce bacteria on the skin . . . \u003Cstrong>Directions\u003C\u002Fstrong>: • wet hands thoroughly with product and allow to dry without wiping….”\u003C\u002Fp>\n\n\u003Cp>ALKEMI HAND SANITIZER GEL packaged in 33.8oz containers resemble drinking water bottles customarily purchased by U.S. consumers\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. Section 502(i)(1) of the FD&amp;C Act, 21 U.S.C. 352(i)(1), provides that a drug is misbranded if “its container is so made, formed, or filled as to be misleading . . .” As such, your clear, colorless hand sanitizer that fills 33.88oz bottle containers that resemble plastic bottles ordinarily used to package drinking water is misbranded under section 502(i)(1) of the FD&amp;C Act, 21 U.S.C. 352(i)(1).\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist in your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent electronically to ORAPHARM4_Responses@fda.hhs.gov or mailed to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, CA 92612\u003C\u002Fp>\n\n\u003Cp>Please identify your response with unique identifier CMS 615066.\u003C\u002Fp>\n\n\u003Cp>If you have any questions regarding this letter, please contact William V. Millar, Compliance Officer, at (503) 671-9711 Ext. 30, or by email at william.millar@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lance M. De Souza\u003Cbr>\nActing Director, Division of Pharmaceutical Quality Operations IV\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nCc:\u003C\u002Fp>\n\n\u003Cp>Morgan Reed\u003Cbr>\nDirector of Operations\u003Cbr>\nChameleon Beverage Co. Inc. dba Chameleon Sanitizer Corporation\u003Cbr>\nmorgan@chameleonbeverage.com\u003C\u002Fp>\n\n\u003Cp>Araceli Ramirez\u003Cbr>\nQuality Control Supervisor\u003Cbr>\nChameleon Beverage Co. Inc. dba Chameleon Sanitizer Corporation\u003Cbr>\naracelir@chameleonbeverage.com\u003C\u002Fp>\n\n\u003Cp>____________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Your gel hand sanitizer drug products contain additional ingredients not described in the guidance and therefore are not exempted.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> FDA is concerned that OTC hand sanitizer drug products packaged in containers that resemble drink containers commonly used by adults and children may confuse or mislead consumers and, thereby, increase the risk of accidental ingestion. Please refer to the August 27, 2020, news release titled, “COVID-19 Update: FDA Warns Consumers About Hand Sanitizer Packaged in Food and Drink Containers,” see \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpress-announcements\u002Fcovid-19-update-fda-warns-consumers-about-hand-sanitizer-packaged-food-and-drink-containers\">https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpress-announcements\u002Fcovid-19-update-fda-warns-consumers-about-hand-sanitizer-packaged-food-and-drink-containers\u003C\u002Fa>, that warns consumers about alcohol-based hand sanitizers packaged in containers that resemble food or drink containers customarily purchased by U.S. consumers may put consumers at risk of serious injury or death if ingested.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Derek W. Reineman\n\nRecipient Title\n\nPresident\n\nChameleon Beverage Co. Inc. dba Chameleon Sanitizer Corporation\n\n6444 E. 26th St\n\nCommerce, CA 90040\n\nUnited States\n\nderekreineman@chameleonbeverage.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nSeptember 24, 2021\n\nDear Mr. Reineman:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, Chameleon Beverage Co. Inc. dba Chameleon Sanitizer Corporation, FEI: 3004378632, at 6444 E. 26th St, Commerce, California, from March 29 to April 2, 2021.\n\nFDA determined that hand sanitizer drug products1 manufactured at your facility were adulterated within the meaning of section 501(a)(2)(A) of the Federal Food, Drug, and Cosmetic (FD&C) Act, 21 U.S.C. 351(a)(2)(A), in that a substance was prepared, packed, or held under insanitary conditions.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, ALKEMI HAND SANITIZER GEL packaged in 33.8oz containers is misbranded under section 502(i) of the FD&C Act, 21 U.S.C. 352(i). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) of the FD&C Act, 21 U.S.C. 331(a). This violation is described in more detail below.\n\nInsanitary Conditions\n\nYour hand sanitizer drug products were adulterated under section 501(a)(2)(A) of the FD&C Act because they were prepared, packed, or held under insanitary conditions. You manufactured batches of hand sanitizer in an unlit (b)(4). The (b)(4) was not (b)(4) and was therefore exposed to the outside environment. Filling was performed by inserting a manual pump into a tote of bulk drug product which was left open to the environment during set-up. You did not have any controls in place to prevent contamination of the production environment and the drug products.\n\nCGMP Violations\n\nWe reviewed your April 23, 2021, response to our Form FDA 483 in detail.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nOur investigators observed that your quality unit (QU) did not provide adequate oversight for the manufacture of your over-the-counter (OTC) drug products. Your firm manufactured hand sanitizer drug products without performing identification testing of the incoming component and without verification of your supplier’s certificates of analysis (COA). Further, you did not establish specifications for the drug product and distributed finished hand sanitizer drug products without performing release testing.\n\nIn your response, you stated that, your agreement with your customer provides that responsibility for hand sanitizer compliance and efficacy rests with your customer. Specifically, both ensuring the quality of incoming components and establishing finished product specifications are the responsibility of your customer. Likewise, you stated that because your customer did not finalize its hand sanitizer formulation and provide finished product specifications, your final product specifications had not been established. As a contract manufacturer, under CGMP, you should not have commenced manufacturing until key quality requirements such as operations and specifications were in place.\n\nYour QU has the responsibility to ensure the quality of components used by your facility and evaluate the quality of finished products to make approval or rejection decisions about each batch. You have quality agreements with several customers regarding the manufacture of hand sanitizer drug products. As a contract manufacturer, quality agreements cannot be used to delegate statutory or regulatory responsibilities to comply with CGMP. You are responsible for the quality of drugs you produce as a contract facility, regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\n\nIn response to this letter, provide the following:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\n• A list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before making a lot disposition decision, and the associated written procedures.\n\n• The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\n\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\n• A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\n\n• A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n\n2. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\n\nYour firm manufactured batches of hand sanitizer by attaching a manual pump to a tote of bulk hand sanitizer for bottle filling. During the inspection, you could not provide cleaning records for the manual pump. Additionally, you could not provide procedures for cleaning and cleaning validation studies for this equipment. The manual pump was observed to be wrapped in plastic tape and rubber gloves and was located in an unlit (b)(4). Bulk hand sanitizer received from several suppliers were filled using this equipment.\n\nFurther, your firm manufactured hand sanitizer drug products on filling line (b)(4) which is also used to manufacture non-pharmaceutical products (i.e., bottled drinking water). During the inspection, you provided an interim cleaning procedure which lacked sufficient detail to ensure adequate cleaning. You also failed to provide validation studies for this cleaning procedure to ensure that cross-contamination does not occur between hand sanitizer drug products and bottled drinking water.\n\nIn your response, you provided a manual pump cleaning procedure that described rinsing the pump with (b)(4) water until the rinse water meets (b)(4) and passes microbial testing. You did not provide validation studies for this method and did not address the adequacy of this method for preventing chemical carry over. Your response did not include a retrospective analysis of the cross-contamination risk between your various drug products and non-drug products.\n\nIn response to this letter, provide the following:\n\n• A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product, including both non-drug products and finished drug products.\n\n• A corrective action preventive action (CAPA) plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\n\nMisbranding Violations\n\nALKEMI HAND SANITIZER GEL is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a consumer topical antiseptic.\n\nExamples of claims observed on the ALKEMI HAND SANITIZER GEL product label that provides evidence of the intended uses (as defined in 21 CFR 201.128) of the product includes, but may not be limited to, the following:\n\n“Drug Facts . . . Uses: • hand sanitizer to reduce bacteria on the skin . . . Directions: • wet hands thoroughly with product and allow to dry without wiping….”\n\nALKEMI HAND SANITIZER GEL packaged in 33.8oz containers resemble drinking water bottles customarily purchased by U.S. consumers2. Section 502(i)(1) of the FD&C Act, 21 U.S.C. 352(i)(1), provides that a drug is misbranded if “its container is so made, formed, or filled as to be misleading . . .” As such, your clear, colorless hand sanitizer that fills 33.88oz bottle containers that resemble plastic bottles ordinarily used to package drinking water is misbranded under section 502(i)(1) of the FD&C Act, 21 U.S.C. 352(i)(1).\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nQuality Systems\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\n(b)(4)\n\nDuring the inspection, (b)(4).\n\nBased upon the nature of the violations we identified at your firm, (b)(4), we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist in your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour response should be sent electronically to ORAPHARM4_Responses@fda.hhs.gov or mailed to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food and Drug Administration\n\n19701 Fairchild Road\n\nIrvine, CA 92612\n\nPlease identify your response with unique identifier CMS 615066.\n\nIf you have any questions regarding this letter, please contact William V. Millar, Compliance Officer, at (503) 671-9711 Ext. 30, or by email at william.millar@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nLance M. De Souza\n\nActing Director, Division of Pharmaceutical Quality Operations IV\n\nCc:\n\nMorgan Reed\n\nDirector of Operations\n\nChameleon Beverage Co. Inc. dba Chameleon Sanitizer Corporation\n\nmorgan@chameleonbeverage.com\n\nAraceli Ramirez\n\nQuality Control Supervisor\n\nChameleon Beverage Co. Inc. dba Chameleon Sanitizer Corporation\n\naracelir@chameleonbeverage.com\n\n____________________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Your gel hand sanitizer drug products contain additional ingredients not described in the guidance and therefore are not exempted.\n\n2 FDA is concerned that OTC hand sanitizer drug products packaged in containers that resemble drink containers commonly used by adults and children may confuse or mislead consumers and, thereby, increase the risk of accidental ingestion. Please refer to the August 27, 2020, news release titled, “COVID-19 Update: FDA Warns Consumers About Hand Sanitizer Packaged in Food and Drink Containers,” see https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpress-announcements\u002Fcovid-19-update-fda-warns-consumers-about-hand-sanitizer-packaged-food-and-drink-containers, that warns consumers about alcohol-based hand sanitizers packaged in containers that resemble food or drink containers customarily purchased by U.S. consumers may put consumers at risk of serious injury or death if ingested.","Chameleon Beverage Co. Inc. dba Chameleon Sanitizer Corporation","chameleon-beverage-co-inc-dba-chameleon-sanitizer-corporation-615066-09242021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchameleon-beverage-co-inc-dba-chameleon-sanitizer-corporation-615066-09242021","2026-10-26T08:08:13.585093+00:00","2021-11-23","615066","DrugsFood & Beverages","Mr. Derek W. Reineman","2026-08-20T02:25:37.748+00:00","2021-09-24",3,{"510k":71,"classification":72,"enforcement":73,"event":74,"event_backfill":75,"pma":76,"warning_letter":77},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]